GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Shiller PE Ratio

Aclaris Therapeutics (FRA:8AT) Shiller PE Ratio : (As of Jun. 02, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aclaris Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Aclaris Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Shiller PE Ratio Chart

Aclaris Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aclaris Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aclaris Therapeutics's Shiller PE Ratio

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Shiller PE Ratio falls into.



Aclaris Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aclaris Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Aclaris Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.221/131.7762*131.7762
=-0.221

Current CPI (Mar. 2024) = 131.7762.

Aclaris Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.000 100.560 0.000
201409 -0.228 100.428 -0.299
201412 -0.248 99.070 -0.330
201503 -0.284 99.621 -0.376
201506 -0.150 100.684 -0.196
201509 -0.535 100.392 -0.702
201512 -0.257 99.792 -0.339
201603 -0.584 100.470 -0.766
201606 -0.552 101.688 -0.715
201609 -0.445 101.861 -0.576
201612 -0.465 101.863 -0.602
201703 -0.449 102.862 -0.575
201706 -0.498 103.349 -0.635
201709 -0.529 104.136 -0.669
201712 -0.625 104.011 -0.792
201803 -0.795 105.290 -0.995
201806 -0.865 106.317 -1.072
201809 -0.908 106.507 -1.123
201812 -0.870 105.998 -1.082
201903 -0.805 107.251 -0.989
201906 -1.071 108.070 -1.306
201909 -1.217 108.329 -1.480
201912 -0.405 108.420 -0.492
202003 -0.335 108.902 -0.405
202006 -0.249 108.767 -0.302
202009 -0.212 109.815 -0.254
202012 -0.247 109.897 -0.296
202103 -0.479 111.754 -0.565
202106 -0.282 114.631 -0.324
202109 -0.298 115.734 -0.339
202112 -0.327 117.630 -0.366
202203 -0.281 121.301 -0.305
202206 -0.293 125.017 -0.309
202209 -0.303 125.227 -0.319
202212 -0.387 125.222 -0.407
202303 -0.392 127.348 -0.406
202306 -0.388 128.729 -0.397
202309 -0.384 129.860 -0.390
202312 -0.018 129.419 -0.018
202403 -0.221 131.776 -0.221

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aclaris Therapeutics  (FRA:8AT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aclaris Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics (FRA:8AT) Business Description

Traded in Other Exchanges
Address
640 Lee Road, Suite 200, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines